Skripsi

Pola Kunjungan Pasien Kanker Buli Pada Era Covid- 19 (2019-2023 ) Di RSCM = Bladder Cancer Patient Visit Patterns In The Covid-19 Era (2019-2023) At RSCM.

Latar Belakang Kanker buli merupakan kanker urogenital terbanyak kedua setelah kanker prostat. Terdata 7.381 kasus baru pada tahun 2022 dengan angka mortalitas 3.207 jiwa di Indonesia. Dunia menghadapi pandemi COVID-19 yang dimulai pada tahun 2019, termasuk Indonesia telah menghadapi pandemi COVID-19 dari tahun 2020-2022 yang menyebabkan layanan kesehatan diprioritaskan untuk kasus COVID-19 sehingga berdampak pada sistem pelayanan kesehatan, termasuk layanan di RSCM. Metode Penelitian ini bertujuan untuk menganalisis jumlah kunjungan pasien kanker buli sebelum, saat, dan setelah pandemi COVID-19 serta melihat pola karakteristik dan pilihan tatalaksana. Studi observasional deskriptif dengan pengambilan data retrospektif dari rekam medis HIS RSCM (2019–2023). Analisis dilakukan secara deskriptif dengan ukuran sampel akhir 224 subjek. Hasil Selama 2019–2023, kunjungan kanker buli di RSCM menunjukkan pola turun–pulih– stabil: menurun pada 2020, meningkat tajam pada 2021, menurun kembali pada 2022, lalu naik lagi pada 2023. Dari 224 pasien, mayoritas laki-laki (169; 75,4%) dan berusia 60–69 tahun (72; 32,1%), berdomisili Jabodetabek (163; 74,1%). Kasus non-metastasis mendominasi (170; 80,6%) dibanding metastasis (41; 19,4%); distribusi stadium didominasi stadium dini (I–II), sementara stadium IV sekitar 24,4% dari kasus. Dalam tatalaksana, TURBT merupakan modalitas terbanyak (82; 43,4%) dengan penurunan pada 2020 dan lonjakan pada 2023; kemoterapi meningkat selama pandemi (2021) lalu menurun kembali pada 2023. Kesimpulan Kunjungan kanker buli di RSCM menunjukkan pola “turun-pulih-stabil” sepanjang 2019–2023, dengan dominasi pasien laki-laki usia lanjut awal dan mayoritas berdomisili Jabodetabek. Pembedahan tetap menjadi modalitas utama. Temuan ini menegaskan perlunya strategi resiliensi layanan (prioritisasi tindakan berisiko tinggi dan penguatan jejaring rujukan) untuk menjaga layanan onkourologi saat terjadi guncangan sistem kesehatan.
Kata Kunci: COVID-19; kanker buli; kunjungan pasien; RSCM


Introduction Bladder cancer is the second most common urogenital malignancy after prostate cancer. In 2022, 7,381 new cases and 3,207 deaths were recorded in Indonesia. The world faced the COVID-19 pandemic beginning in 2019; Indonesia experienced the pandemic from 2020 to 2022, during which healthcare services were prioritized for COVID-19 cases, impacting the health system, including services at RSCM. Method This study aimed to determine the number of bladder cancer patient visits before, during, and after the COVID-19 pandemic and to examine patterns in patient characteristics and treatment choices. An observational study with retrospective data collection was conducted using RSCM’s Hospital Information System (HIS) (2019–2023). Descriptive analyses were performed, with a final sample size of 224 subjects. Results From 2019 to 2023, bladder cancer visits at RSCM followed a decline–recovery– stabilization pattern: a decrease in 2020, a sharp increase in 2021, a decrease in 2022, and a rise again in 2023. Of 224 patients, most were male (169; 75.4%), aged 60–69 years (72; 32.1%), and resided in Jabodetabek (163; 74.1%). Non-metastatic cases predominated (170; 80.6%) over metastatic cases (41; 19.4%); stage distribution was dominated by early stages (I–II), while stage IV accounted for about 24.4% of cases. Regarding management, TURBT was the most frequent modality (82; 43.4%), declining in 2020 and surging in 2023; chemotherapy increased during the pandemic (2021) and decreased again by 2023. Conclusion Bladder cancer visits at RSCM showed a “decline–recovery–stabilization” pattern over 2019–2023, with a predominance of older male patients and most residing in Jabodetabek. Surgery remained the main treatment modality. These findings underscore the need for service resilience strategies (prioritizing high-risk procedures and strengthening referral networks) to maintain uro-oncology services during health-system shocks.
Keywords: COVID-19; bladder cancer; patient visits; RSCM.